Cibinetide
Appearance
Clinical data | |
---|---|
Other names | ARA-290; ARA290; PHBSP; pHBSP peptide; pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser; Pyroglutamate helix B surface peptide; UEQLERALNSS |
Drug class | Erythropoietin receptor agonist[1][2] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C51H84N16O21 |
Molar mass | 1257.324 g·mol−1 |
3D model (JSmol) | |
| |
|
Cibinetide (INN ; USAN ; developmental code name ARA-290) is an erythropoietin receptor agonist which is under development for the treatment of a variety of different medical conditions.[1][2][3] It was also under development for the treatment of depressive disorders, but development for this indication was discontinued.[1] The drug is under development by Araim Pharmaceuticals.[1][2]
References
[edit]- ^ a b c d "Cibinetide - Araim Pharmaceuticals". AdisInsight. 28 June 2022. Retrieved 23 October 2024.
- ^ a b c "Delving into the Latest Updates on Cibinetide with Synapse". Synapse. 8 October 2024. Retrieved 23 October 2024.
- ^ Peng B, Kong G, Yang C, Ming Y (February 2020). "Erythropoietin and its derivatives: from tissue protection to immune regulation". Cell Death Dis. 11 (2): 79. doi:10.1038/s41419-020-2276-8. PMC 6997384. PMID 32015330.